Biography

Prof. Ramón Cacabelos

Camilo José Cela University, Spain

 

Email: [email protected]

 

Qualifications

1985 Ph.D., Doctor in Medicine and Surgery, Santiago University Medical School, Santiago de Compostela, Spain

1980 M.D., Graduate in Medicine and Surgery. Oviedo University Medical School, Oviedo, Spain

 

Publications (Selected)

  1. Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimer’s disease. Acta Neurol. Scand., 102 (Suppl. 176):12-19 (2000).
  2. Cacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).
  3. Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Min. Rev. Medic. Chem., 2:59-84 (2002).
  4. Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).
  5. Cacabelos, R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics, 4:597-621 (2003).
  6. Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimer’s disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).
  7. Cacabelos, R., Corzo, L., Fernández-Novoa, L., Lombardi, V. Histamine in Alzheimer’s disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).
  8. Cacabelos, R., Fernández-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).
  9. Cacabelos, R., Fernández-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimer’s disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).
  10. Cacabelos, R. Genomic characterization of Alzheimer’s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).
  11. Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimer’s disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).
  12. Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health, 1:303-348 (2005).
  13. Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).
  14. Cacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future, 31(Suppl. B):5-146 (2006).
  15. Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).
  16. Takeda, M., Cacabelos, R. (Eds.). Alzheimer’s disease genomics. Cognition and Dementia, 6 (Suppl.):7-113 (2007).
  17. Cacabelos, R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).
  18. Cacabelos, R., Llovo, R., Fraile, C., Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).
  19. Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol. Diag. Ther., 11:385-405 (2007).
  20. Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).
  21. Cacabelos, R. Influence of pharmacogenetic factors on Alzheimer’s disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).
  22. Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Meth Mol. Biol., 448:213-357 (2008).
  23. Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).
  24. Cacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).
  25. Cacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).

 

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top